Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Parabilis Medicines, Inc.
Alliance for Clinical Trials in Oncology
AstraZeneca
Agenus Inc.